VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
The approval of a capital band through 2030 gives VERAXA the ability to raise funds more efficiently without requiring repeated shareholder votes, which is crucial for a biotechnology company that may need to access capital markets quickly to finance clinical trials or scale up manufacturing. Increasing the board size from five to seven members allows for the addition of directors with expertise in areas such as regulatory strategy, commercial operations, or specific therapeutic areas, strengthening oversight as the company moves its pipeline toward later-stage development.
VERAXA focuses on antibody-based cancer therapeutics, including bispecific T cell engagers and bispecific ADCs. Its BiTAC platform is designed to improve the efficacy and safety of cancer treatments. The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned research institution.
The strong shareholder vote—over 99.94% in favor—indicates confidence in management’s strategy, which is important for a pre-commercial biotech company where investor support is critical for funding ongoing research and development. With these governance changes, VERAXA may be better positioned to pursue partnership opportunities or acquisitions that could accelerate its pipeline progress.
Full details of the shareholder meeting results are available in the company’s press release. For ongoing updates, the company’s newsroom can be accessed here.
This approval comes at a time when the biotech sector faces a challenging financing environment, making the flexibility provided by the capital band and conditional share capital particularly valuable. The ability to issue shares or warrants without additional shareholder meetings could allow VERAXA to act swiftly when favorable financing opportunities arise. The increase in board size also permits the recruitment of directors with financial or operational expertise to guide the company through its next growth phase.
Overall, the shareholder vote positions VERAXA to execute its strategy with greater agility, potentially accelerating the development of its oncology pipeline and creating long-term value for shareholders.
